These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29963728)

  • 1. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
    Urick ME; Bell DW
    Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
    Urick ME; Bell DW
    Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
    Urick ME; Yu EJ; Bell DW
    Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
    Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
    BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
    Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
    Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
    Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
    Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
    Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
    Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
    Koo J; Wu X; Mao Z; Khuri FR; Sun SY
    J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent insight into the role of FBXW7 as a tumor suppressor.
    Yumimoto K; Nakayama KI
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
    Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
    Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCF(FBXW7)-mediated degradation of p53 promotes cell recovery after UV-induced DNA damage.
    Galindo-Moreno M; Giráldez S; Limón-Mortés MC; Belmonte-Fernández A; Reed SI; Sáez C; Japón MÁ; Tortolero M; Romero F
    FASEB J; 2019 Oct; 33(10):11420-11430. PubMed ID: 31337255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of tumor suppressors changes the endometrial tumor spectrum.
    Mayo LD
    EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FBXW7: a critical tumor suppressor of human cancers.
    Yeh CH; Bellon M; Nicot C
    Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
    Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
    [No Abstract]   [Full Text] [Related]  

  • 18. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
    Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
    Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
    Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway.
    Liu L; Jiang H; Wang X; Wang X; Zou L
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.